Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Myeloid 1Gastrointestinal 1

Conditions

Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Infusions, Intravenous × Clear all
NCT03238248 2024-11-04

Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
71 enrolled 13 charts
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT01023958 2017-11-22

Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer

Boehringer Ingelheim

Phase 2 Completed
50 enrolled 29 charts
Tumor-Agnostic

Neoplasms

NCT00399035 2016-12-28

HORIZON II

AstraZeneca

Phase 3 Completed
1,254 enrolled 14 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡